Can Fite Valuation
| CANF Stock | 2.60 0.10 3.70% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Can Fite Biopharma shows a prevailing Real Value of 2.25 per share. The current price of the firm is 2.6. Our model approximates the value of Can Fite Biopharma from analyzing the firm fundamentals such as Operating Margin of (13.51) %, shares outstanding of 1.01 B, and Return On Equity of -1.34 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
Please note that Can Fite's price fluctuation is risky at this time. Calculation of the real value of Can Fite Biopharma is based on 3 months time horizon. Increasing Can Fite's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Can Fite Biopharma is useful when determining the fair value of the Can stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Can Fite. Since Can Fite is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Can Stock. However, Can Fite's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.6 | Real 2.25 | Hype 2.6 |
The real value of Can Stock, also known as its intrinsic value, is the underlying worth of Can Fite Biopharma Company, which is reflected in its stock price. It is based on Can Fite's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Can Fite's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Can Fite's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Can Fite Biopharma helps investors to forecast how Can stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Can Fite more accurately as focusing exclusively on Can Fite's fundamentals will not take into account other important factors: Can Fite Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Can Fite's current stock value. Our valuation model uses many indicators to compare Can Fite value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Can Fite competition to find correlations between indicators driving Can Fite's intrinsic value. More Info.Can Fite Biopharma is number one stock in price to earning category among related companies. It is number one stock in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Can Fite by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Can Fite's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Can Fite's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Can Fite's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Can Fite and how it compares across the competition.
About Can Fite Valuation
The stock valuation mechanism determines the current worth of Can Fite Biopharma on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Can Fite Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Can Fite Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Can Fite's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Can Fite's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Can Fite. We calculate exposure to Can Fite's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Can Fite's related companies.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel. CAN FITE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 7 people.
8 Steps to conduct Can Fite's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Can Fite's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Can Fite's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Can Fite's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Can Fite's revenue streams: Identify Can Fite's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Can Fite's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Can Fite's growth potential: Evaluate Can Fite's management, business model, and growth potential.
- Determine Can Fite's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Can Fite's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Can Fite Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |